We aim to cover the following topics:
- The rationale for targeting DDR, including PARP inhibition as the proof of concept.
- The mechanism of action of PARP inhibitors.
- Role of diagnostics, and how diagnostics ensure appropriate patient selection.
- Current role of PARP inhibition in clinical practice, including:
- The efficacy and safety/tolerability profile of PARP inhibitors.
- The potential benefit of PARP inhibitors in various tumour types.
- The appropriate patient selection for PARP inhibition.
- The current indications for PARP inhibition in clinical practice.
- Anticipate the potential future application of targeting DDR in clinical practice, including
- The potential combination strategies with PARP inhibitors.
- The potential future role of targeting DDR in clinical practice, including drugs with a novel mode of action and their potential combination strategies.
- The potential future indications for targeting DDR and PARP inhibition and the rationale for targeting DDR in these indications.
- The potential future role of diagnostics in DDR.
Module 1 provides an introduction to PARP inhibitors
Module 2 provides an overview of the DDR pathway in health and disease, including cancer.
Information on cancer drugs known as DDR (DNA damage response)-targeting agents and PARP (poly-ADP ribose polymerase) inhibitors